Review Article

Global Meta-Analysis on the Association between Behcet Syndrome and Polymorphisms from the HLA Class I (A, B, and C) and Class II (DRB1, DQB1, and DPB1) Genes

Cristina Capittini,1 Chiara Rebuffi,2 Marco Vincenzo Lenti,3 Antonio Di Sabatino,3 Carmine Tinelli,1 Miryam Martinetti,4 and Annalisa De Silvestri4

1Scientific Direction, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
2IRCCS Istituto Giannina Gaslini, Scientific Direction, Italy
3First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy
4University of Pavia, Italy

Correspondence should be addressed to Cristina Capittini; cristina.capittini@libero.it

Received 15 August 2021; Revised 17 November 2021; Accepted 23 November 2021; Published 13 December 2021

Academic Editor: Miriana D’Alessandro

Copyright © 2021 Cristina Capittini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Behcet syndrome (BS) is a multisystemic perivasculitis whose genetic susceptibility is linked to HLA region. We first meta-analysed all HLA class I and II genes involved in BS susceptibility in all ethnic groups worldwide. We identified 1141 articles and finally included 31 case-control studies after multiple rounds of selection. We analysed frequencies for 24 HLA-A alleles (3 alleles for HLA-A*26 at four digits), 50 HLA-B alleles (11 alleles for HLA-B*51 at four digits), 15 HLA-C alleles, 16 HLA-DRB1 alleles, 6 HLA-DQB1 alleles, and 15 HLA-DPB1 alleles. We meta-analysed only HLA allelic frequencies from at least three studies; therefore, we investigated 21 alleles out of 140. Going from 7.00 to 1.6 OR, we found 11 class I alleles conferring risk for BS: HLA-B*51:08, HLA-B*51:01, HLA-B*51:02, HLA-DQB1*03, A*26:01, Cw*14, Cw*15, Cw*16, B*15, and A*26.

Overall, the studies included populations from Europe (Greece, Spain, Italy, Germany, and Ireland), Asia (Korea, China, China Han, and Thailand), Middle East (Israel, Saudi Arabia, and Iran), and Morocco (as no other North-African population was included). We collected a number of ethnical groups sufficient to conduct an ethnic-specific meta-analysis where Europeans showed 11.25 OR for HLA-B*51:08 and Japan 3.50 OR for A*26:01. A remarkable result was that the most frequent HLA-B*51 two-digit alleles associated with BS were different among populations: HLA-B*51:08 in Europe, HLA-B*51:01 in Turkey, and HLA-B*51:02 in Japan. Overall, we discussed our real-world results with other imputation studies.

1. Introduction

Behcet syndrome (BS) is an autoinflammatory multisystemic neutrophilic perivasculitis characterized by recurrent inflammatory flares causing protean clinical manifestations [1].

Although the diagnosis is based only on clinical signs set by the International Criteria for Behçet’s Disease (ICBD), from a genetic point of view, the disease has been historically linked first to human leukocyte antigen- (HLA-) B5 serotype, then to the HLA-B51 molecule/allele [2].

The geographic distribution of BS over the centuries shows a connection with specific populations, in particular those ones settled along the Silk Road, which is a network of trade routes connecting East Asia with Southern Europe passing through Middle East lands and East Africa [3].

The HLA region shows an extensive variation in the number of both genes and alleles. HLA genes are the most polymorphic ones in the human genome, and more than 8450 alleles have been discovered at the HLA-B locus. It is worldwide accepted that the extensive polymorphism of the HLA region is the result of selective pressures driven by the functional role of HLA molecules in the immune response. In fact, the highest degree of polymorphism is toward the peptide-binding region [4].
From 2009 onwards, seven genome-wide association studies (GWAS) in BS have been published. Overall, the following subjects were analysed in worldwide GWAS: 2576 Turkish BS with 2728 healthy controls; 975 Japanese BS with 1013 healthy controls; 336 Western Europeans, Middle Eastern, and Turkish BS with 5843 healthy ethnically matched controls; 379 Korean BS with 800 healthy controls; and 703 Chinese BS with 2110 healthy controls [5–11].

Fei and colleagues performed the first genome-wide association study in a cohort of 152 Turkish BS patients and 172 healthy ethnically matched controls [5]. They identified genetic associations between BS and the following single-nucleotide polymorphisms (SNPs): rs317711 (7p15-p14) in CPVL (carboxypeptidase vitellogenic-like, expressed on human macrophages and trimming peptides for antigen presentation); rs4936742 (11q24) in UBAH3B (ubiquitin-associated and SH3 domain containing B, promotes accumulation of T-cell receptors and EGFR on the cell surface); rs9513584 (13q32) in UBAC2 (ubiquitin-associated domain (UBA) containing 2, negatively regulates the canonical Wnt signaling pathway in the lymphocytes); and rs2061634 (9q22) in KIAA1529 and rs11206377 (1p34) in KLRC4 (NKRF2-F type II integral membrane protein, a receptor for the recognition of MHC class I HLA-E molecules by NK cells) (12p13.2). They also found two SNPs in ERAP1 (endoplasmic reticulum aminopeptidase 1 that trims peptide for the generation of most HLA class I-binding peptides) (5q15). They also found evidence for interaction between HLA-B*51 and ERAP1 [10].

Kappen and colleagues performed a GWAS on 336 Turkish, Western Europeans, and Middle Eastern BD cases and 5843 multiethnic birth cohort (from the Netherlands), using linear regression models corrected for population stratification. They identified SNPs mapping to the HLA region (6p21.33) [11].

Overall, all these GWAS showed a limited number of novel locus associations. In fact, also using the most advanced molecular techniques, the HLA region still remains the most involved in BS susceptibility, mostly in Turkish patients.

Another issue concerns the unequal distribution of BS among different ethnic groups, and the use of GWAS and bioinformatics tools in cohorts of mixed ethnicity does not seem to be an effective solution.

This is the first meta-analysis that considers all HLA class I and II genes involved in BS susceptibility in all ethnic groups worldwide.

2. Materials and Methods

This study followed the PRISMA guidelines [12].

2.1. Protocol. We drafted a protocol including: review question, eligibility criteria, primary and secondary endpoints, search strategy, methods for data extraction, study quality assessment, risk of bias assessment, strategy for data synthesis, and statistical methodology.

On April 29th 2019, the protocol entitled “Association between HLA class I (A, B, and C) and class II (DRB1, DQB1, and DPB1) polymorphisms and Behcet Syndrome: a meta-analysis” was published in the PROSPERO International prospective register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO/CRD42019130390).

2.2. Search Strategy. We performed a systematic search in PubMed, Embase, Web of Science, and Scopus databases, retrieving all publications (case-control, cross-sectional, and retrospective cohort studies or mixed design) on the association between HLA class I and II alleles and Behcet Syndrome (BS) in adult patients (>18 years).

We searched all English, Italian, Spanish, French, and Turkish-written articles published in up to December 2020. An expert librarian performed the search using the following MeSH terms: ("Behcet Syndrome") AND ("HLA" OR...
“human leukocyte antigen”) AND (“polymorphism” OR “variant” OR “genotype” OR “allele”).

Selection criteria were as follows:

(1) HLA class I and II genes and any A, B, C, DRB1, DQB1, DQA1, and DRB1 alleles or molecules

(2) BS diagnosed following the clinical criteria set by the following:

(i) International study group for Behcet’s disease, Criteria for diagnosis of Behcet’s disease, Lancet, 1990; 335: 1078–1080 [1]

(ii) International Team for the Revision of the International Criteria for Behcet’s disease (ICBD) Clinical and Experimental Rheumatology. 2006; 24(supplement 42): p. S13 [13]

(iii) International Team for the Revision of the International Criteria for Behcet’s Disease. Revision of the International Criteria for Behcet’s Disease (ICBD) Clinical and Experimental Rheumatology. 2006; 24(supplement 42):S14–S15 [14]

(iv) International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014; 28(3):338–347 [15]

(v) Behcet’s Disease Research Committee of Japan. Behcet’s disease guide to the diagnosis of Behcet’s disease (1972) Japanese Journal of Ophthalmology. 1974; 18 : 291–294 [16]

(vi) Mizushima Y. Recent research into Behcet’s disease in Japan. International Journal of Tissue Reactions. 1988; 10(2):59–65 [17]

2.3 Risk of Bias Assessment. Following a quality assessment tool for genetic data (Quality Assessment of Genetic Studies in Systematic Reviews, QUAGENS) [18], proposed by our multidisciplinary panel (statisticians, clinical epidemiologists, immunogeneticists, clinicians, and meta-analysts), three pairs of reviewers (one for the clinical criteria, one for laboratory issues, and one for methodology tools) working independently and with adequate reliability verified the following aspects:

(1) Clinical data: the presence of spectrum disease biases, the possible enrollment of incident or prevalent cases, the inclusion of controls not selected from the same source population as the case-subjects, and the occurrence of differential participation in cases and controls

![Flow diagram of the study following the PRISMA guidelines.](image-url)
(2) Laboratory issues: the misclassification of genotypes or serotypes (including the types and quality of samples, timing of collection, and the method used for HLA typing), the actual laboratory staff blinded to outcome, and the mention of quality controls

(3) Methodological features: the possible population stratification, the presence of multiple testing and prestudy odds of true finding (it would be useful interpreting the results in the context of how many polymorphisms have been studied), and the assessment of HW equilibrium in controls

Each question was answered as “yes,” “no,” or “unclear.”

2.4. Data Extraction. After a critical reading of full-text articles, two investigators independently performed data extraction according to the selection criteria. The third participant was consulted for discussion to reach agreement concerning discrepancies. The following items were extracted from each study: first author’s last name, publication date, country of origin, numbers of cases and controls, and typing method.

2.5. Data Synthesis and Meta-Analysis. STATA and MetaDiSc was used for statistical analysis to perform the meta-analysis. Heterogeneity was checked by the chi-squared test and the I-squared statistics [19]. Statistical heterogeneity was defined by a P value < 0.10 for the chi-squared test and an I-squared statistics > 50%.

When there was no statistical evidence for heterogeneity in effect sizes, the fixed-effect model was used [20] to meta-analyze ORs or RRs in probands; when significant heterogeneity was identified, the random-effects model was used [21] to explore sources of significant heterogeneity. Also, a subgroup analysis stratified by ethnicity was performed.

3. Results

3.1. Study Characteristics and Quality Assessment. Following the search strategy, we identified 1141 articles, and after multiple rounds of selection, 68 articles were chosen for a full-text evaluation, of which 31 were included in the meta-analysis; 26 of them reported only the frequencies for the HLA – B*51 allele [22–47].

Figure 1 shows the flow diagram according to the PRISMA statement [12].

The quality of studies in terms of laboratory method description, statistical methodology, and clinical features is depicted in Figure 2.
and retrieved frequencies for 24 HLA-A alleles and 3 alleles for HLA – A * 26 at four digits, 50 HLA-B alleles and 11 alleles for HLA – B * 51 at four digits, 15 HLA-C alleles, 16 HLA-DRB1 alleles, 6 HLA-DQB1 alleles, and 15 HLA-DPB1 alleles.

We evaluated the strength of the association between specific HLA alleles and the susceptibility to BS considering both predisposing and protective alleles. We meta-analysed only HLA allelic frequencies from at least three studies; therefore, we investigated only 21 alleles out of 140. Egger’s regression test showed no evidence of publication bias (Egger’s regression test P values < 0.1).

Table 1 lists the number of Behcet syndrome (BS) patients and the ethnically matched controls and the results of the meta-analyses carried out for each HLA allele to verify the correlation with susceptibility or protection to BS.

| HLA     | OR   | P       | N of BD | N of CTR | N of studies |
|---------|------|---------|---------|----------|--------------|
| B * 51 : 08 | 7.00 | <0.0001 | 503     | 962      | 8            |
| B * 51 | 5.81 | <0.0001 | 1895    | 7799     | 26           |
| B * 51 : 01 | 5.54 | <0.0001 | 988     | 1571     | 13           |
| B * 51 : 02 | 3.14 | 0.008   | 544     | 625      | 8            |
| DQB1 * 03 | 2.60 | <0.0001 | 153     | 399      | 4            |
| A * 26 : 01 | 2.48 | <0.0001 | 432     | 1705     | 4            |
| Cw * 14 | 2.35 | 0.001   | 279     | 260      | 4            |
| Cw * 15 | 2.34 | 0.001   | 279     | 260      | 4            |
| Cw * 16 | 2.23 | 0.014   | 279     | 260      | 4            |
| B * 15 | 1.79 | 0.004   | 433     | 5479     | 5            |
| A * 26 | 1.70 | <0.0001 | 523     | 1781     | 7            |
| B * 35 | 0.69 | 0.008   | 691     | 5763     | 10           |
| Cw * 07 | 0.69 | 0.035   | 370     | 400      | 5            |
| B * 52 | 0.58 | 0.007   | 715     | 855      | 10           |
| B * 07 | 0.55 | 0.007   | 658     | 5698     | 9            |
| Cw * 03 | 0.55 | 0.002   | 237     | 302      | 3            |
| A * 33 | 0.53 | <0.0001 | 661     | 1852     | 6            |
| B * 18 | 0.53 | 0.017   | 580     | 623      | 8            |
| DRB1 * 13 | 0.51 | 0.015   | 267     | 554      | 6            |
| B * 54 | 0.36 | <0.0001 | 445     | 501      | 3            |
| DQB1 * 05 | 0.36 | 0.002   | 121     | 89       | 3            |

3.3. Ethnicity-Specific Meta-Analysis. Overall, the studies included populations from Europe (Greece, Spain, Italy, Germany, and Ireland), Asia (Korea, China, China Han, and Thailand), Middle East (Israel, Saudi Arabia, and Iran), and Morocco (as no other North-African population was included).

Due to the higher frequency of BS among Japanese and Turkish people, we considered studies from Japanese and Turkish samples separately.

We collected a number of ethnical groups sufficient to conduct an ethnic-specific meta-analysis. Table 2 lists the OR from the HLA alleles for each ethnic subgroup.

4. Discussion

Since 1978, the autoinflammatory Behcet syndrome (BS) has been linked to the HLA (human leukocyte antigen) genetic system. Using serotype tests, BS was first linked to the HLA-B51 molecule; later, using molecular testing, BS was linked to the HLA-B51 allele, which is still the strongest genetic BS marker [43].

Going from the HLA-B gene to the telomere region of chromosome 6, we have HLA-C and HLA-A genes, while going from the HLA-B gene to the centromere region, we have HLA class III genes (not included in this study) and HLA class II genes, such as HLA-DRB1, HLA-DQB1, and HLA-DPB1.

Here, for the first time, we meta-analysed the HLA class I and II genes involved in BS susceptibility in all ethnic worldwide groups, collecting HLA genetic data from 31 case-control studies and retrieved allelic frequencies for the HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, and HLA-DPB1 genes.

Our data confirmed the HLA-B51 allele as the genetic HLA marker mostly associated with BS development all over the world among all different ethnic samples (OR 5.81, P < 0.0001) (Figure 3).

Notably, considering high-resolution two-digit analysis of the HLA-B51 allele, we observed that the HLA – B * 51 : 08 variant showed the highest OR associated with BS (OR = 7.00, P < 0.001) (Table 1), followed by the two-digit HLA – B * 51 : 01 and HLA – B * 51 : 02 alleles (Table 1). Moreover, in our set of Europeans, the HLA – B * 51 : 08 variant showed a 11.25 OR (Table 2).

Our results are in line with the work by Guasp and colleagues where high-resolution HLA – B * 51 alleles were associated with epitaxis with Hap10, a low-activity variant of ERAP1 (endoplasmic reticulum aminopeptidase 1), although its pathogenic role in BS is still unclear. In particular, the authors studied the effects of Hap10 on the HLA – B * 51 peptidome aiming at distinguishing the different effects of this epitaxis with high-resolution HLA – B * 51 polymorphisms in BS [47]. The HLA – B * 51 : 08 BS-associated peptidome expressed in a Hap10-positive cell line was compared with the HLA – B * 51 : 01 peptidome from cells expressing more active ERAP1 variants. The authors
estimated that peptide-binding affinity and the HLA – B * 51 : 08 peptidome generated longer peptides. They concluded that the BS-associated Hap10 haplotype induces changes in the repertoire of peptides presented to HLA – B * 51 altering its antigen-presenting specificity and generating a lower affinity peptidome [45].

In our analysis we also observed an association with BS with the HLA – A * 26 : 01 allele (HLA class I), the HLA

---

**Table 2: Meta-analysis for ethnic subgroups. Values are odds ratio (OR) and confidence interval (CI) in parentheses.**

| Study ID | OR (95% CI) | Events, treatment | Events, control | % weight |
|----------|-------------|-------------------|-----------------|----------|
| A * 26 : 01 | 2.48 (1.8-3.5) | 1/28 | 25/5000 | 1.15 |
| A * 15 | 1.79 (1.2-2.7) | 26/96 | 17/111 | 4.44 |
| A * 25 | 4.66 (2.9-7.3) | 105/174 | 47/191 | 5.70 |
| A * 30 | 9.15 (4.5-15.0) | 114/180 | 27/170 | 5.37 |
| A * 35 | 3.90 (2.4-7.4) | 41/86 | 19/104 | 4.65 |
| A * 40 | 11.50 (2.9-47.4) | 15/26 | 5/28 | 2.14 |
| A * 45 | 3.75 (1.9-7.2) | 36/76 | 19/104 | 4.57 |
| A * 50 | 9.27 (4.5-18.7) | 67/120 | 12/100 | 4.39 |
| A * 55 | 8.00 (4.2-18.9) | 52/91 | 20/140 | 4.75 |
| A * 60 | 3.51 (1.5-8.0) | 36/58 | 14/44 | 3.82 |
| A * 65 | 10.89 (3.8-30.6) | 27/53 | 19/65 | 3.02 |
| A * 70 | 6.25 (2.7-14.2) | 44/75 | 10/54 | 3.82 |
| A * 75 | 11.67 (3.1-41.5) | 24/120 | 10/112 | 3.99 |
| A * 80 | 11.67 (2.5-51.7) | 24/120 | 10/112 | 3.99 |
| A * 85 | 11.67 (2.5-51.7) | 24/120 | 10/112 | 3.99 |

**Figure 3: Forest plot from the meta-analysis for the HLA – B * 51 allele.**
Cw *14, HLA – Cw *15, and HLA – Cw *16 alleles (HLA class I) and with HLA – DQB1 *03 allele (HLA class II) (Table 1).

As to HLA – A *26 risk allele, our real-world data are a confirmation of the results imputed by Ombrello and colleagues, who inferred in 2014 the independent role of HLA-B51 and HLA-A26 in BS susceptibility by imputed MHC-region SNPs and also found HLA – B *15 to be an independent BS risk [48]. Moreover, we observed in a sample of 600 healthy subjects (personal unpublished data) that the HLA – A *26;B *51 haplotype was not the most frequent among HLA-A:B haplotypes (seventh place), thus further confirming with our real-world data the results by Ombrello and colleagues [48].

Regarding the association between BS and HLA-C alleles, Hughes and colleagues genotyped 8572 SNPs to infer classical HLA alleles in the HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DQB1, and HLA-DRB1 genes from 2 ancestry groups, and they imputed data suggesting a robust HLA – B *51 association with BS and an additional independent genetic association with HLA – Cw *16 : 02 [49]. In agreement with imputed data by Hughes and colleagues, in our sample of 600 healthy Caucasian subjects (personal unpublished data), we observed that the HLA – B *51;Cw *15 and HLA – B *51;Cw *14 haplotypes were the second and third most frequent haplotypes, while the HLA – B *51;Cw *16 haplotype was the sixth place, thus supporting an independent role of HLA – B *51 and HLA – Cw *16 in BS.

Finally, we found that the HLA – DQB1 *03 was a BS risk allele (Table 1). To take into account all possible bias due to some linkage, we also observed in the same sample of 600 healthy subjects (personal unpublished data) that the frequency of the B *51;DQB1 *03 haplotype was the second place.

Piga and colleagues found the HLA-A2; Cw2; B *5101; DRB1 *11; DQA1 *05; DQB1 *03 haplotype in a subset of BS patients; however, the authors also found that the HLA-A2; Cw2; B *5101; DRB1 *04; DQA1 *03; DQB1 *03 haplotype was not associated with BS, thus highlighting the importance of studying extended HLA haplotypes rather than single alleles [50].

Finally, we considered populations from Europe (Greece, Spain, Italy, Germany, and Ireland), Asia (Korea, China, China Han, and Thailand), Middle-East (Israel, Saudi Arabia, and Iran), and Morocco (as no other North-African population was included), and we separately considered studies from Japanese and Turkish samples due to their higher frequency of BS.

In our study, the most remarkable result was that the most frequent HLA – B *51 two-digit alleles associated with BS were different in different populations: in Europe, the HLA – B *51 : 08 (OR 11.25 C.I. 4.9-26), in Turkey the HLA – B *51 : 01 (OR 5.98 C.I. 3.7-9.8), and in Japan the HLA – B *51 : 02 (OR 5.39 C.I. 0.6-47) (Table 2).

On the whole, HLA – B *51 is no more the only flag tagging a genetic marker to BS susceptibility; in fact, we observed that HLA-A and HLA-C variants also play an independent role in BS risk.

Beyond the distribution of HLA variants related to different ethnicities, we suggest that a further study ought to be focused on the correlation between these HLA – B *51 two-digit variants (in particular HLA – B *51 : 08) and clinical signs.

5. Conclusion

Despite remarkable different results on the distribution of the two-digit HLA – B *51 alleles associated with BS among populations, unfortunately, we could not find sufficient data on the association between HLA alleles and different clinical features. This comparison should be a further goal in order to find also clinically relevant differences in treatment response.

Data Availability

Data is available at http://www.crd.york.ac.uk/PROSPERO/CRD42019130390

Conflicts of Interest

The authors declare no conflict of interests.

References

[1] International study group for Behcet’s disease, ”Criteria for diagnosis of Behcet’s disease,” Lancet, vol. 335, pp. 1078-1080, 1990.
[2] S. Ohno, T. Asanuma, S. Sugiura, A. Wakisaka, M. Aizawa, and K. Itakura, ”HLA-Bw51 and Behcet’s disease,” JAMA, vol. 240, no. 6, p. 529, 1978.
[3] M. Piga and A. Mathieu, ”Genetic susceptibility to Behcet’s disease: role of genes belonging to the MHC region,” Rheumatology (Oxford, England), vol. 50, no. 2, pp. 299–310, 2011.
[4] M. A. Fernandez Vina, J. A. Hollenbach, K. E. Lyke et al., ”Tracking human migrations by the analysis of the distribution of HLA alleles, lineages and haplotypes in closed and open populations,” Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, vol. 367, no. 1590, pp. 820–829, 2012.
[5] Y. Fei, R. Webb, B. L. Cobb, H. Direskeneli, G. Saruhan-Direskeneli, and A. H. Sawalha, ”Identification of novel genetic susceptibility loci for Behçet’s disease using a genome-wide association study,” Arthritis Research & Therapy, vol. 11, no. 3, p. R66, 2009.
[6] E. F. Remmers, F. Cosan, Y. Kirino et al., ”Genome-wide association study identifies variants in the MHC class I, _IL10_ , and _IL23R-IL12RB2_ regions associated with Behçet’s disease,” Nature Genetics, vol. 42, no. 8, pp. 698–702, 2010.
[7] N. Mizuki, A. Meguro, M. Ota et al., ”Genome-wide association studies identify _IL10_ as Behçet’s disease susceptibility loci,” Nature Genetics, vol. 42, no. 8, pp. 703–706, 2010.
[8] S. Hou, Z. Yang, L. Du et al., ”Identification of a susceptibility locus in STAT4 for Behcet’s disease in Han Chinese in a genome-wide association study,” Arthritis and Rheumatism, vol. 64, no. 12, pp. 4104–4113, 2012.
[9] Y. J. Lee, Y. Horie, G. R. Wallace et al., ”Genome-wide association study identifies GIMAP as a novel susceptibility locus for
Behcet's disease,” *Annals of the Rheumatic Diseases*, vol. 72, no. 9, pp. 1510–1516, 2013.

[10] Y. Kirino, G. Bertsias, Y. Ishigatsubo et al., “Genome-wide association analysis identifies new susceptibility loci for Behcet’s disease and epitope between _HLA-B*51_ and _ERAP1_,” *Nature Genetics*, vol. 45, no. 2, pp. 202–207, 2013.

[11] J. H. Kappen, C. Medina-Gomez, P. M. van Hagen et al., “Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease,” *PLoS One*, vol. 10, no. 3, article e0119085, 2015.

[12] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and PRISMA Group, “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement,” *Journal of Clinical Epidemiology*, vol. 62, no. 10, article 1006e12, pp. 1006–1012, 2009.

[13] International Team for the Revision of the International Criteria for Behcet’s Disease, “Evaluation of the International Criteria for Behcet’s Disease (ICBD),” *Clinical and Experimental Rheumatology*, vol. 24, supplement 42, p. S13, 2006.

[14] International Team for the Revision of the International Criteria for Behcet’s Disease, “Revision of the International Criteria for Behcet’s Disease (ICBD),” *Clinical and Experimental Rheumatology*, vol. 24, supplement 42, pp. S14–S15, 2006.

[15] “The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria,” *Journal of the European Academy of Dermatology and Venereology*, vol. 28, no. 3, pp. 338–347, 2014.

[16] Behcet’s Disease Research Committee of Japan, “Behcet’s disease guide to the diagnosis of Behcet’s disease (1972),” *Japanese Journal of Ophthalmology*, vol. 18, pp. 291–294, 1974.

[17] Y. Mizushima, “Recent research into Behcet’s disease in Japan,” *International Journal of Tissue Reactions*, vol. 10, no. 2, pp. 59–65, 1988.

[18] A. De Silvestri, C. Capitini, and A. Pasi, “QUAGENS: a tool for QUnity Assessment of GENetic Studies in systematic reviews,” A proposal, 2016, Evidencelive16 Oxford http://evidencelive.org/wp-content/uploads/2016/06/DE-SILVESTRI-22.pdf.

[19] J. P. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” *Statistics in Medicine*, vol. 21, no. 11, pp. 1539–1558, 2002.

[20] N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” *Journal of the National Cancer Institute*, vol. 22, no. 4, pp. 719–748, 1959.

[21] R. Der Simonian and N. Laird, “Meta-analysis in clinical trials,” *Controlled Clinical Trials*, vol. 7, no. 3, pp. 177–188, 1986.

[22] M. de Menthon, M. P. Lalavalle, C. Maldini, L. Guillemin, and A. Mahr, “HLA-B51/B5 and the risk of Behcet’s disease: a systematic review and meta-analysis of case–control genetic association studies,” *Arthritis and Rheumatism*, vol. 61, no. 10, pp. 1287–1296, 2009.

[23] Z. Touma, C. Farra, A. Hamdan et al., “TNF polymorphisms in patients with Behçet disease: a meta-analysis,” *Archives of Medical Research*, vol. 41, no. 2, pp. 142–146, 2010.

[24] Y. H. Lee and G. G. Song, “Associations between eNOS polymorphisms and susceptibility to Behcet’s disease: a meta-analysis,” *Journal of the European Academy of Dermatology and Venereology*, vol. 26, no. 10, pp. 1266–1271, 2012.

[25] C. Maldini, M. P. Lalavalle, M. Cheminant, M. de Menthon, and A. Mahr, “Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies,” *Rheumatology (Oxford, England)*, vol. 51, no. 5, pp. 887–900, 2012.

[26] Y. H. Lee, S. J. Choi, J. D. Ji, and G. G. Song, “Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to vasculitis: a meta-analysis,” *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 13, no. 1, pp. 196–201, 2012.

[27] Y. H. Lee and G. G. Song, “CTLA-4 polymorphisms and susceptibility to Behcet’s disease: a meta-analysis,” *Molecular Biology Reports*, vol. 39, no. 9, pp. 9041–9045, 2012.

[28] Y. J. Zhang, W. D. Xu, Z. H. Duan, S. S. Liu, H. F. Pan, and D. Q. Ye, “Lack of association between CTLA-4 +49A/G and -318C/T polymorphisms and Behcet’s disease risk: a meta-analysis,” *Clinical and Experimental Rheumatology*, vol. 30, 3 Suppl 72, pp. S46–S50, 2012.

[29] M. Zhang, W. D. Xu, P. F. Wen et al., “Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet’s disease: an updated meta-analysis,” *Molecular Vision*, vol. 19, pp. 1913–1924, 2013.

[30] G. G. Song, J. H. Kim, and Y. H. Lee, “The chemokine receptor 5 delta32 polymorphism and type 1 diabetes, Behcet’s disease, and asthma: a meta-analysis,” *Immunological Investigations*, vol. 43, no. 2, pp. 123–136, 2014.

[31] J. Zou and J. L. Guan, “Interleukin-1-related genes polymorphisms in Turkish patients with Behçet disease: a meta-analysis,” *Modern Rheumatology*, vol. 24, no. 2, pp. 321–326, 2014.

[32] Y. Liang, W. D. Xu, M. Zhang et al., “Meta-analysis of association between cytokine gene polymorphisms and Behcet’s disease risk,” *International Journal of Rheumatic Diseases*, vol. 16, no. 6, pp. 616–624, 2013.

[33] J. Zou and J. L. Guan, “Intercellular adhesion molecule-1 polymorphisms in patients with Behçet disease: a meta-analysis,” *Modern Rheumatology*, vol. 24, no. 3, pp. 481–486, 2014.

[34] N. Wei, Z. Chen, Z. Xue, and Y. Zhu, “Polymorphism of VEGF gene in susceptibility to chronic immune-mediated inflammatory diseases: a meta-analysis,” *Rheumatology International*, vol. 35, no. 8, pp. 1351–1360, 2015.

[35] Z. Wu, S. Zhang, J. Li et al., “Association between MEFV mutations M694V and M680I and Behcet’s disease: a meta-analysis,” *PLoS One*, vol. 10, no. 7, article e0132704, 2015.

[36] Y. H. Lee and Song GG2, “Associations between major histocompatibility complex class I chain-related gene A polymorphisms and susceptibility to Behcet’s disease. A meta-analysis,” *Zeitschrift für Rheumatologie*, vol. 74, no. 8, pp. 714–721, 2015.

[37] L. Ortiz-Fernández, J. R. García-Lozano, M. A. Montes-Cano et al., “Association of CCR5Δ32 and Behcet’s disease: new data from a case-control study in the Spanish population and meta-analysis,” *Clinical and Experimental Rheumatology*, vol. 33, 6 Suppl 94, pp. S96–S100, 2015.

[38] Y. Xu, K. Zhou, Y. Zhu et al., “Association of cytokine gene polymorphisms (IL-6, IL-12B, IL-18) with Behcet’s disease: a meta-analysis,” *Zeitschrift für Rheumatologie*, vol. 75, no. 9, pp. 932–938, 2016.

[39] J. Zhang, D. Liao, L. Yang et al., “Association between functional MICA-TM and Behcet’s disease: a systematic review and meta-analysis,” *Scientific Reports*, vol. 6, no. 1, article 21033, 2016.

[40] Z. Mirfeizi, S. Tabaei, Y. Ravanshad, H. Hashemzadeh, E. Kharazmi, and H. Mehrad-Majd, “Associations between...
vitamin D receptor polymorphisms and susceptibility to Behçet’s disease: a meta-analysis,” *Immunological Investigations*, vol. 47, no. 4, pp. 389–402, 2018.

[41] W. Louthrenoo, N. Kasitano, K. Pathanapitoon et al., “Contribution of HLA-B*51:01 and -A*26:01 to Behçet’s disease and their clinical association in Thai patients,” *International Journal of Rheumatic Diseases*, vol. 23, no. 2, pp. 247–255, 2020.

[42] S. A. Muñoz, A. O. Orden, A. Kostianovsky et al., “El alelo HLA-B*51 se asocio fuertemente a la Enfermedad de Behçet en la poblacion argentina,” *Reumatología Clínica*, vol. 16, no. 4, pp. 282–285, 2020.

[43] H. Yazici, E. Seyahi, G. Hatemi, and Y. Yazici, “Behçet syndrome: a contemporary view,” *Nature Reviews Rheumatology*, vol. 14, no. 2, pp. 107–119, 2018.

[44] S. Ohno, M. Ohguchi, S. Hirose, H. Matsuda, A. Wakisaka, and M. Aizawa, “Close association of HLA-Bw51 with Behçet’s disease,” *Archives of Ophthalmology*, vol. 100, no. 9, pp. 1455–1458, 1982.

[45] P. Guasp, E. Barnea, M. F. González-Escribano et al., “Processing of the HLA-B*51:08 peptidome by ERAP1,” *The Journal of Biological Chemistry*, vol. 292, no. 23, pp. 9680–9689, 2017.

[46] F. Adeeb, W. L. Ng, M. U. Khan, J. Devlin, A. G. Stack, and A. D. Fraser, “The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet’s disease,” *European Journal of Rheumatology*, vol. 4, no. 4, pp. 254–259, 2017.

[47] F. Choukri, A. Chakib, H. Himmich, S. Hüe, and S. Caillat-Zucman, “HLA-B*51 and B*15 alleles confer predisposition to Behçet’s disease in Moroccan patients,” *Human Immunology*, vol. 62, no. 2, pp. 180–185, 2001.

[48] M. J. Ombrello, Y. Kirino, P. I. de Bakker, A. Gül, D. L. Kastner, and E. F. Remmers, “Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 24, pp. 8867–8872, 2014.

[49] T. Hughes, P. Coit, A. Adler et al., “Identification of multiple independent susceptibility loci in the HLA region in Behçet’s disease,” *Nature Genetics*, vol. 45, no. 3, pp. 319–324, 2013.

[50] M. Piga, F. Paladini, S. Lai et al., “Genetics of Behçet’s disease in Sardinia: two distinct extended HLA haplotypes harbour the B*51 allele in the normal population and in patients,” *Clinical and Experimental Rheumatology*, vol. 30, 3 Suppl 72, pp. S51–S56, 2012.